IMUX · Immunic, Inc. · Executive Compensation
Market Cap
$127.51M
Shares
13.64M
Volume · Oct 5
491.26K
Avg daily vol (3M)
269.59K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Daniel Vitt | CEO | $2,938,223 |
| Dr. Duane Nash | Chairman | $1,211,828 |
| Glenn Whaley | CFO | $1,171,957 |
| Jason Tardio | COO | $1,030,219 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Daniel Vitt | CEO | $1,211,839 |
| Glenn Whaley | CFO | $702,206 |
| Dr. Duane Nash | Chairman | $648,925 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Daniel Vitt | Chief Executive Officer, President | $2,557,171 |
| Glenn Whaley | Chief Financial Officer | $1,476,010 |
| Dr. Andreas Muehler | Chief Medical Officer | $1,464,733 |
| Dr. Duane Nash | Executive Chairman | $1,068,590 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dr. Daniel Vitt | Chief Executive Officer, President | $1,935,915 |
| Dr. Duane Nash | Executive Chairman | $1,407,137 |
| Dr. Andreas Muehler | Chief Medical Officer | $1,291,756 |
| Glenn Whaley | Chief Financial Officer The amounts in the “Option Awards” column reflect the aggregate grant date fair value of stock options granted during the calendar year computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate these amounts are discussed in Note 7 to our financial statements appearing at the end of our Annual Report on Form 10-K for the year ended December 31, 2022. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. An exchange rate of 1.056 Euro to based on the average exchange rate for 2022 was used to convert payment amounts in euros for the table above for both 2021 and 2022 to make the salaries and bonus more comparable year over year. See also footnotes & below re 2021 amounts. Dr. Vitt received payment of his salary in Euros. Dr. Muehler received payment in both and Euros. For Dr. Muehler, represents a pension allowance. For 2022 and 2021, the amount in the “Salary” column represents combined compensation for service as Executive Chairman and the cash retainer payable for service on the Company’s board of directors. In the 2021 proxy statement, the 2021 salary was converted using a rate of 1.18 and the reported salary and bonus for Daniel Vitt was 446,040 and 175,628. In the 2021 proxy statement, the 2021 salary was converted using a rate of 1.18 and the reported salary and bonus for Andreas Muehler was 398,506 and 122,042, respectively. | $928,331 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Duane Nash | Executive Chairman | $2,199,796 |
| Dr. Daniel Vitt | Chief Executive Officer, President | $1,318,054 |
| Dr. Andreas Muehler | Chief Medical Officer | $934,748 |
| Glenn Whaley | Chief Financial Officer | $848,288 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dr. Daniel Vitt | Chief Executive Officer, President | $2,383,932 |
| Dr. Andreas Muehler | Chief Medical Officer | $2,118,072 |
| Dr. Manfred Gröppel | Chief Operating Officer | $1,866,067 |
| Russell J. Cox | Former Chief Executive Officer | $1,215,890 |
| Duane D. Nash | M.D., J.D. Former Chief Executive Officer | $964,198 |
| Dr. Duane Nash | Executive Chairman | $308,650 |
| Glenn Whaley | Principal Financial and Accounting Officer | $98,701 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Russell J. Cox | Former Chief Executive Officer | $8,056,689 |
| Duane D. Nash | M.D., J.D. Former Chief Executive Officer | $753,152 |
| Dr. Andreas Muehler | Chief Medical Officer | — |
| Dr. Daniel Vitt | Chief Executive Officer, President | — |
| Dr. Manfred Gröppel | Chief Operating Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Duane Nash | member of the Board of Directors | Resigned | 2026-09-11 |
| Erik Lundgren | Director of the Board | Appointed | 2026-08-11 |
| Michael W. Bonney | Chair of the Board of Directors | Appointed | 2026-08-11 |
| Michael A. Panzara | Chief Medical Officer | Appointed | 2026-08-11 |
| Erik Lundgren | Chief Executive Officer | Appointed | 2026-08-11 |
| Daniel Vitt | Founder and Chair of the Company's Scientific Advisory Board | Appointed | 2026-08-11 |
| Daniel Vitt | Chief Executive Officer | Resigned | 2026-08-11 |
| Daniel Vitt | member of the Board | Resigned | 2026-08-11 |
| Elena Ridloff | member of the Board | Appointed | 2026-08-11 |
| Erik Lundgren | Class II director | Appointed | 2026-07-06 |
| Tamar Howson | member of the Compensation Committee of the Board of Directors and as a member of the Board | Resigned | 2026-07-06 |
| Richard Rudick | Class III Director | Appointed | 2026-06-29 |
| Thorvald Nagel | Class III Director | Appointed | 2026-06-29 |
| Michael Bonney | Class III Director | Appointed | 2026-06-29 |
| Erik Lundgren | Chief Executive Officer | Appointed | 2026-05-27 |
| Daniel Vitt | Chief Executive Officer | Resigned | 2026-05-27 |
| Erik Lundgren | Chief Executive Officer | Appointed | 2026-05-27 |
| Michael W. Bonney | Chair of the Board | Appointed | 2026-05-19 |
| Michael A. Panzara | Chief Medical Officer | Appointed | 2026-04-28 |
| Andreas Rolf Muehler | member of the Executive Board of Immunic AG | Resigned | 2026-04-28 |
| Andreas Rolf Muehler | Chief Medical Officer | Terminated | 2026-04-28 |
| Andreas Muehler, M.D., M.B.A. | Chief Medical Officer | Resigned | 2026-04-28 |
| Michael A. Panzara, M.D., M.P.H. | Chief Medical Officer | Appointed | 2026-04-28 |
| Jon Congleton | member of the board of directors | Appointed | 2026-03-31 |
| Thor Nagel | member of the Board of Directors | Appointed | 2026-02-13 |